Karen M. Xu

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial

Ashesh B. Jani, Eduard Schreibmann, Subir Goyal et al. · The Lancet · 2021 · 178 citations · Full text

Positron Emission Tomography, Surgical Oncology, Postprostatectomy Salvage Radiotherapy +15

Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: A National Cancer Data Base (NCDB) study

Malolan S. Rajagopalan, Karen M. Xu, Jeff Lin et al. · Gynecologic Oncology · 2014 · 66 citations

Vaginal Cancer, Cancer Epidemiology, Radiation Therapy +8

Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma

Kimmen Quan, Philip Sutera, Karen M. Xu et al. · Practical Radiation Oncology · 2017 · 42 citations

Surgical Oncology, Pancreatic Cancer, Radiation Therapy +7

Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

Karen M. Xu, Karthik Ramesh, Vicki Huang et al. · Tomography · 2022 · 26 citations · Full text

Patterns of care and brachytherapy boost utilization for vaginal cancer in the United States

Malolan S. Rajagopalan, Karen M. Xu, Jeff Lin et al. · Practical Radiation Oncology · 2014 · 24 citations

Vaginal Cancer, Medicine, Cancer Management +9